Xtl Biopharmaceuticals (XTLB) Gross Profit (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted Gross Profit of -$43000.0 for Q4 2024, down 125.9% sequentially from $166000.0 in Q3 2014.

Xtl Biopharmaceuticals (XTLB) Gross Profit (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals has reported Gross Profit for 5 years, with the latest figure at -$43000.0 in Q4 2024.

Quarterly Gross Profit changed N/A year-over-year to -$43000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $820000.0 (changed N/A YoY) and the FY2024 annual result came in at $3000.0, changed N/A from the prior year.
Gross Profit fell to -$43000.0 in Q4 2024 per XTLB's latest filing, from $166000.0 in the prior quarter.
Over five years, Gross Profit peaked at -$43000.0 in Q4 2024 and troughed at -$43000.0 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Xtl Biopharmaceuticals	2.64 Bn	2.64 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	-43,000.00
Dec 31, 2024	-43,000.00
Sep 30, 2014	166,000.00
Sep 30, 2014	166,000.00
Jun 30, 2014	267,000.00
Jun 30, 2014	267,000.00
Mar 31, 2014	430,000.00
Mar 31, 2014	430,000.00
Dec 31, 2013	537,000.00
Dec 31, 2013	537,000.00
Sep 30, 2013	293,000.00
Sep 30, 2013	293,000.00
Jun 30, 2013	324,000.00
Jun 30, 2013	324,000.00
Mar 31, 2013	474,000.00
Mar 31, 2013	474,000.00
Dec 31, 2012	371,000.00
Dec 31, 2012	371,000.00
Sep 30, 2012	187,000.00
Sep 30, 2012	187,000.00